NCT00753740 2020-06-12
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Lumos Pharma
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT01380769 2020-05-28
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed